<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>                     <BR>                     <BR>                     Clinical Studies<BR>                     <BR>                        Tretinoin has been investigated in 114 previously treated APL patients and in 67 previously untreated (“de novo”) patients in one open-label, uncontrolled single investigator clinical study (Memorial Sloan-Kettering Cancer Center [MSKCC]) and in two cohorts of compassionate cases treated by multiple investigators under the auspices of the National Cancer Institute (NCI). All patients received 45 mg/m2/day as a divided oral dose for up to 90 days or 30 days beyond the day that CR was reached. Results are shown in the following table:<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="491" ID="id_4bf0d191-5b4b-4ffc-afb3-d771591bb5cc"><BR>                           <col width="26.1%"/><BR>                           <col width="12.0%"/><BR>                           <col width="12.0%"/><BR>                           <col width="12.0%"/><BR>                           <col width="13.8%"/><BR>                           <col width="12.0%"/><BR>                           <col width="12.0%"/><BR>                           <tfoot ID="id_8bcaf752-59ec-4310-bf27-b36a759735a1"><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule" colspan="7">NR = Not Reached<br/>NA = Not Available</td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr ID="id_7712eb32-48fa-4b48-97ca-ea90d2af70c8"><BR>                                 <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule"/><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule">MSKCC</td><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule">NCI Cohort 1</td><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule">NCI Cohort 2</td><BR>                              </tr><BR>                              <tr ID="id_7ea1fcb4-1c67-4742-aadd-6e6336344ac4"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>Relapsed</paragraph>n=20</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>De Novo</paragraph>n=15</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>Relapsed<footnote ID="id-c472025f-7556-4faf-97b9-554709386c04">Including 9 chemorefractory patients</footnote><BR>                                    </paragraph>n=48</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>De Novo</paragraph>n=14</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>Relapsed</paragraph>n=46</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>De Novo<footnote ID="id-57b73bad-3aae-41bc-b755-3e4b0df306df">Including 8 patients who received chemotherapy but failed to enter remission</footnote><BR>                                    </paragraph>n=38</td><BR>                              </tr><BR>                              <tr ID="id_94f9dc93-725d-4b20-8abb-6a3bd0381559"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <paragraph>Complete Remission </paragraph><BR>                                    <paragraph>Median Survival (Mo) </paragraph><BR>                                    <paragraph>Median Follow-up (Mo) </paragraph>RA-APL Syndrome</td><BR>                                 <td align="center" valign="top" styleCode="Rrule"><BR>                                    <paragraph>16 (80%)</paragraph><BR>                                    <paragraph>10.8</paragraph><BR>                                    <paragraph>9.9</paragraph>4 (20%)</td><BR>                                 <td align="center" valign="top" styleCode="Rrule"><BR>                                    <paragraph>11 (73%)</paragraph><BR>                                    <paragraph>NR</paragraph><BR>                                    <paragraph>42.9</paragraph>5 (33%)</td><BR>                                 <td align="center" valign="top" styleCode="Rrule"><BR>                                    <paragraph>24 (50%)</paragraph><BR>                                    <paragraph>5.8</paragraph><BR>                                    <paragraph>5.6</paragraph>10 (21%)</td><BR>                                 <td align="center" valign="top" styleCode="Rrule"><BR>                                    <paragraph>5 (36%)</paragraph><BR>                                    <paragraph>0.5</paragraph><BR>                                    <paragraph>1.2</paragraph>6 (43%)</td><BR>                                 <td align="center" valign="top" styleCode="Rrule"><BR>                                    <paragraph>24 (52%)</paragraph><BR>                                    <paragraph>8.8</paragraph><BR>                                    <paragraph>8</paragraph>NA</td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <paragraph>26 (68%)</paragraph><BR>                                    <paragraph>NR</paragraph><BR>                                    <paragraph>13.1</paragraph>NA</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>The median time to CR was between 40 and 50 days (range: 2 to 120 days). Most patients in these studies received cytotoxic chemotherapy during the remission phase. These results compare to the 30% to 50% CR rate and, ≤ 6 month median survival reported for cytotoxic chemotherapy of APL in the treatment of relapse.<BR>                        Ten of 15 pediatric cases achieved CR (8 of 10 males and 2 of 5 females). There were insufficient patients of black, Hispanic or Asian derivation to estimate relative response rates in these groups, but responses were seen in each category. <BR>                        Responses were seen in 3 of 4 patients for whom cytogenetic analysis failed to detect the t(15;17) translocation typically seen in APL. The t(15;17) translocation results in the PML/RARα gene, which appears necessary for this disease. Molecular genetic studies were not conducted in these cases, but it is likely they represent cases with a masked translocation giving rise to PML/RARα. Responses to tretinoin have not been observed in cases in which PML/RARα fusion has been shown to be absent.<BR>                     <BR>                     <BR>                  <BR>               </P></DIV></HTML>